InMode (INMD) Stock Price, News & Analysis

Company Overview

InMode Ltd. develops, manufactures and markets a broad range of medical aesthetic devices that leverage energy‐based technologies to deliver minimally invasive and noninvasive treatments. Its solutions employ radiofrequency, light and ultrasound to address skin tightening, body contouring, facial rejuvenation and various surgical applications. The company’s product portfolio includes platforms such as BodyTite, FaceTite and Morpheus8, which are designed to promote tissue coagulation, contraction and remodeling with reduced downtime compared to traditional surgical procedures.

Founded in 2008 in Israel by Dr. Moshe Mizrahy, InMode has grown from a single energy‐based technology venture into a publicly traded entity, listing on the NASDAQ in 2019 under the ticker INMD. Over the years, the company has expanded its global footprint, establishing direct sales operations and distribution partnerships across North America, Europe, Asia Pacific and Latin America. InMode’s solutions are cleared by key regulatory bodies, including the U.S. Food and Drug Administration and the European CE marking process, supporting a presence in more than 90 countries worldwide.

InMode’s devices are utilized by dermatologists, plastic surgeons and medical professionals for a range of aesthetic and clinical procedures. Beyond core face and body applications, the company offers specialized systems such as Evolve for hands‐free body remodeling and Optimas, a multi‐application platform that integrates treatments like Fractora, Lumecca and AccuTite. This modular approach allows practitioners to tailor procedures, optimizing patient outcomes while streamlining clinic workflows.

Leadership at InMode is led by founder and Chief Executive Officer Dr. Moshe Mizrahy, who brings extensive experience in RF and surgical technologies. The executive team emphasizes research and development, dedicating a significant portion of revenue to the advancement of next‐generation energy devices. By focusing on innovation, safety and ease of use, InMode aims to drive adoption of minimally invasive treatments and maintain its position as a leader in the rapidly evolving medical aesthetics market.

Key Stats

• Today's Range: $15.12 to $15.40
• 50-Day Range: $13.28 to $15.21
• 52-Week Range: $13.14 to $19.85
• Volume: 595,953 shs
• Average Volume: 1.23 million shs
• Market Capitalization: $957.95 million
• P/E Ratio: 6.50
• Dividend Yield: N/A
• Price Target: $18.54
• Consensus Rating: Hold

InMode Stock Analysis - MarketRank™

InMode scored higher than 67% of companies evaluated by MarketBeat, and ranked 320th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

InMode has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

InMode has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.00%

Earnings Growth

Earnings for InMode are expected to grow by 4.00% in the coming year, from $1.75 to $1.82 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InMode is 6.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of InMode is 6.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.64.

Price to Book Value per Share Ratio

InMode has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.21% of the float of InMode has been sold short.

Short Interest Ratio / Days to Cover

InMode has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InMode has recently decreased by 2.17%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InMode does not currently pay a dividend.

Dividend Growth

InMode does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.21% of the float of InMode has been sold short.

Short Interest Ratio / Days to Cover

InMode has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InMode has recently decreased by 2.17%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.79

News Sentiment

InMode has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for InMode this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for INMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added InMode to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InMode insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.92% of the stock of InMode is held by insiders.

Percentage Held by Institutions

68.04% of the stock of InMode is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INMD Stock Analysis - Frequently Asked Questions

How have INMD shares performed this year?

InMode's stock was trading at $16.70 at the beginning of 2025. Since then, INMD shares have decreased by 9.3% and is now trading at $15.1550.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings results on Monday, April, 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.14. The firm's quarterly revenue was down 3.0% on a year-over-year basis.
Read the conference call transcript.

When did InMode's stock split?

Shares of InMode split before market open on Thursday, September 30th 2021.The 2-1 split was announced on Friday, September 17th 2021. The newly created shares were payable to shareholders after the closing bell on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does InMode have any subsidiaries?

InMode subsidiaries include these companies: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..

When did InMode IPO?

InMode (INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

How do I buy shares of InMode?

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InMode investors own include Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Voya Infrastructure, Industrials and Materials Fund (IDE), Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK) and Waste Connections (WCN).

Company Calendar

• Last Earnings: 4/28/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:INMD
• CIK: 1742692
• Web: www.inmodemd.com
• Phone: 972-4909-7470
• Fax: N/A
• Employees: 480
• Year Founded: 2008

Price Target and Rating

• Average Stock Price Target: $18.54
• High Stock Price Target: $25.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +22.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.33
• Trailing P/E Ratio: 6.50
• Forward P/E Ratio: 8.66
• P/E Growth: N/A
• Net Income: $181.27 million
• Net Margins: 44.79%
• Pretax Margin: 35.64%
• Return on Equity: 17.17%
• Return on Assets: 15.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.73
• Quick Ratio: 7.86

Sales & Book Value

• Annual Sales: $394.82 million
• Price / Sales: 2.43
• Cash Flow: $1.82 per share
• Price / Cash Flow: 8.31
• Book Value: $10.12 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 63,210,000
• Free Float: 58,835,000
• Market Cap: $957.95 million
• Optionable: Optionable
• Beta: 1.95